Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Gastric Cancer Drugs Market Valued at Present and by 2029?

Over the past few years, there’s been a significant upsurge in the size of the vasodilators market. It’s set to escalate from $6.4 billion in 2024 to $6.76 billion in 2025, witnessing a compound annual growth rate (CAGR) of 5.7%. Factors contributing to this growth in the previous period include heightened awareness and diagnoses, governmental initiatives and healthcare regulations, improving health consciousness among the populace, developments in gene therapy, and the rising adoption of artificial intelligence.

The financial prediction for the vasodilators market indicates robust growth in the near future. It is anticipated to reach ” $8.45 billion by 2029, with a compound annual growth rate (CAGR) of 5.7%. This surge during the projected period is credited to the increasing occurrence of hypertension and heart-related conditions, heightened demand for innovative medical technology for heart ailments, the growth of the elderly population worldwide, and an increasing incidence of diabetes and high blood pressure. Another contributing factor is the growing emphasis on personalized medicine. Some major trends expected in this projection period include strategic partnerships and buyouts, a shift towards outpatient settings and home-based care, product innovation, advancements in technology, and healthcare infrastructure growth.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16565&type=smp

#What Drivers Are Influencing Growth In The Gastric Cancer Drugs Market?

The rise in obesity and the growing number of smokers have led to an increase in people being afflicted with gastric cancer. Unhealthy dietary habits and tobacco consumption escalate the danger of developing stomach cancer. As cited by the UK’s Government Digital Service, it was estimated in May 2023 that the obesity rate amongst individuals aged 18 and above in England had grown from 25.2% in 2022 to 25.9%. As the number of gastric cancer cases rises, so does the demand for gastric cancer medications, thus promoting market growth.

The vasodilators market covered in this report is segmented –

1) By Type: Arterial Dilators, Venous Dilators, Mixed Dilators

2) By Drugs: Nitroglycerin, Alprostadil, Minoxidil, Sorbitrate, Other Drugs

3) By Indication: Hypertension, Angina, Heart Failure, Other Indications

4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

5) By End User: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By Arterial Dilators: Calcium Channel Blockers, Nitric Oxide Donors, Potassium Channel Activators

2) By Venous Dilators: Nitrates, Nitrites, Phosphodiesterase Inhibitors (PDE5 Inhibitors)

3) By Mixed Dilators: Alpha-Adrenergic Antagonists, Angiotensin II Receptor Blockers (ARBs), ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)

How Are Key Trends Driving Expansion In The Gastric Cancer Drugs Industry?

Primary players in the vasodilators market are concentrating on the invention of advanced commodities such as soluble guanylate cyclase (sGC) stimulators, to secure a dominant position in the market. Soluble guanylate cyclase (sGC) is an enzyme typically found in cells, especially those in the smooth muscle cells present in blood vessels. This enzyme is capable of converting guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP) when activated, leading to an increase in blood flow through vasodilation. As an example, Bayer AG, a pharmaceutical and biotechnology firm based in Germany, introduced Vericiguat (Verquvo) in September 2022. It is a soluble guanylate cyclase (sGC) stimulator for adults suffering from symptomatic chronic heart failure. The drug points a pathway that existing treatments do not, thus lowering the chance of cardiovascular death and hospitalization.

Which Companies Play A Key Role In The Development Of The Gastric Cancer Drugs Market?

Major companies operating in the vasodilators market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc., Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., AstraZeneca, Mayo Foundation for Medical Education and Research (MFMER), Boehringer Ingelheim International GmbH, Bayer AG, Viatris Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

What Are The Key Regional Developments Shaping The Gastric Cancer Drugs Market?

North America was the largest region in the vasodilators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vasodilators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16565&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model